← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy + platinum doublet

nivolumab + ipilimumab + platinum-doublet chemotherapy · Bristol Myers Squibb

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for adults with metastatic or recurrent non-small cell lung cancer without EGFR or ALK genomic tumor aberrations, using two cycles of platinum-doublet chemotherapy with nivolumab and ipilimumab.

LAMPGEN ANALYSIS

Why it matters

Added a dual immunotherapy regimen with a short initial chemotherapy course and no PD-L1 cutoff.

What research teams should watch

Separate the two chemotherapy cycles from the continuing immunotherapy schedule and document driver status.

PRIMARY RECORDS

Sources